These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15750629)

  • 41. Adiponectin deficiency limits tumor vascularization in the MMTV-PyV-mT mouse model of mammary cancer.
    Denzel MS; Hebbard LW; Shostak G; Shapiro L; Cardiff RD; Ranscht B
    Clin Cancer Res; 2009 May; 15(10):3256-64. PubMed ID: 19447866
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
    Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
    Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Altered AIB1 or AIB1Δ3 expression impacts ERα effects on mammary gland stromal and epithelial content.
    Nakles RE; Shiffert MT; Díaz-Cruz ES; Cabrera MC; Alotaiby M; Miermont AM; Riegel AT; Furth PA
    Mol Endocrinol; 2011 Apr; 25(4):549-63. PubMed ID: 21292825
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Conditional deletion of β-catenin in mammary epithelial cells of Ron receptor, Mst1r, overexpressing mice alters mammary tumorigenesis.
    Wagh PK; Zinser GM; Gray JK; Shrestha A; Waltz SE
    Endocrinology; 2012 Jun; 153(6):2735-46. PubMed ID: 22474186
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer.
    Arendt LM; Rugowski DE; Grafwallner-Huseth TA; Garcia-Barchino MJ; Rui H; Schuler LA
    Breast Cancer Res; 2011 Jan; 13(1):R11. PubMed ID: 21276249
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Validation of transgenic models of breast cancer: ductal carcinoma in situ (DCIS) and Brca1-mutation-related breast cancer.
    Frech MS; Jones LP; Furth PA
    Breast Cancer Online; 2005 Aug; 8(8):. PubMed ID: 24371431
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Embryonic mammary signature subsets are activated in Brca1-/- and basal-like breast cancers.
    Zvelebil M; Oliemuller E; Gao Q; Wansbury O; Mackay A; Kendrick H; Smalley MJ; Reis-Filho JS; Howard BA
    Breast Cancer Res; 2013 Mar; 15(2):R25. PubMed ID: 23506684
    [TBL] [Abstract][Full Text] [Related]  

  • 48. WAP-TAg transgenic mice and the study of dysregulated cell survival, proliferation, and mutation during breast carcinogenesis.
    Li M; Lewis B; Capuco AV; Laucirica R; Furth PA
    Oncogene; 2000 Feb; 19(8):1010-9. PubMed ID: 10713684
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
    Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
    Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
    [No Abstract]   [Full Text] [Related]  

  • 50. Hormonal and dietary modulation of mammary carcinogenesis in mouse mammary tumor virus-c-erbB-2 transgenic mice.
    Yang X; Edgerton SM; Kosanke SD; Mason TL; Alvarez KM; Liu N; Chatterton RT; Liu B; Wang Q; Kim A; Murthy S; Thor AD
    Cancer Res; 2003 May; 63(10):2425-33. PubMed ID: 12750262
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inducible and coupled expression of the polyomavirus middle T antigen and Cre recombinase in transgenic mice: an in vivo model for synthetic viability in mammary tumour progression.
    Rao T; Ranger JJ; Smith HW; Lam SH; Chodosh L; Muller WJ
    Breast Cancer Res; 2014 Jan; 16(1):R11. PubMed ID: 24457046
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability.
    McCormack SJ; Weaver Z; Deming S; Natarajan G; Torri J; Johnson MD; Liyanage M; Ried T; Dickson RB
    Oncogene; 1998 May; 16(21):2755-66. PubMed ID: 9652742
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reduced Brca1 protein expression in 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced rat mammary carcinomas.
    Okochi E; Miyamoto K; Wakazono K; Shima H; Sugimura T; Ushijima T
    Mol Carcinog; 2002 Aug; 34(4):211-8. PubMed ID: 12203372
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Establishment of an in vitro estrogen-dependent mouse mammary tumor model: a new tool to understand estrogen responsiveness and development of tamoxifen resistance in the context of stromal-epithelial interactions.
    Pontiggia O; Rodriguez V; Fabris V; Raffo D; Bumaschny V; Fiszman G; de Kier Joffé EB; Simian M
    Breast Cancer Res Treat; 2009 Jul; 116(2):247-55. PubMed ID: 18622696
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Heterozygosity for a mutation in Brca1 or Atm does not increase susceptibility to ENU-induced mammary tumors in Apc(Min)/+ mice.
    Karabinis ME; Larson D; Barlow C; Wynshaw-Boris A; Moser AR
    Carcinogenesis; 2001 Feb; 22(2):343-6. PubMed ID: 11181458
    [TBL] [Abstract][Full Text] [Related]  

  • 56. p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma.
    Shibata MA; Maroulakou IG; Jorcyk CL; Gold LG; Ward JM; Green JE
    Cancer Res; 1996 Jul; 56(13):2998-3003. PubMed ID: 8674054
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis.
    Lubet RA; Boring D; Steele VE; Ruppert JM; Juliana MM; Grubbs CJ
    Cancer Prev Res (Phila); 2009 Feb; 2(2):161-7. PubMed ID: 19196723
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of Estrogen Signaling Reduces the Incidence of
    Baek HJ; Kim SE; Choi EK; Kim JK; Shin DH; Park EJ; Kim TH; Kim JY; Kim KG; Deng CX; Kim SS
    Int J Biol Sci; 2018; 14(12):1755-1768. PubMed ID: 30416390
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Conditional expression of Ki-Ras
    Andò S; Malivindi R; Catalano S; Rizza P; Barone I; Panza S; Rovito D; Emprou C; Bornert JM; Laverny G; Metzger D
    Oncogene; 2017 Nov; 36(46):6420-6431. PubMed ID: 28745321
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tamoxifen-resistant, ER-positive MAC 51 cell line with a high metastatic potential developed from a spontaneous breast cancer mouse model.
    Kumar JM; Kombairaju P; Nagarajan P; Subramanian T; Jose J; Ganapathy HS; Ohsugi T
    Cell Tissue Res; 2012 Nov; 350(2):347-60. PubMed ID: 22868912
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.